Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Glimpse Group, Inc. Director's Dealing 2024

Mar 5, 2024

34791_dirs_2024-03-05_d75c774d-b12a-42e4-8cd8-4eeecebd3b11.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Glimpse Group, Inc. (VRAR)
CIK: 0001854445
Period of Report: 2024-02-29

Reporting Person: Bentovim Lyron L (Director, President and CEO)

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2024-02-29 Stock Option (Right to Purchase) $ D 90188 Disposed Common Stock (90188) Direct
2024-03-01 Stock Option (Right to Purchase) $ A 72153 Acquired 2031-03-01 Common Stock (72153) Direct

Footnotes

F1: Represents the forfeiture of fully vested options to purchase an aggregate of 90,188 shares of common stock granted under the issuer's 2016 equity incentive plan, as amended (the "2016 Plan"), consisting of options to purchase (i) 32,508 shares of common stock granted on August 1, 2018 with an exercise price of $4.00/share, (ii) 6,037 shares of common stock and 4,799 shares of common stock granted on September 1, 2019 with an exercise price of $4.00/share, (iii) 22,222 shares of common stock and 6,674 shares of common stock granted on January 1, 2020 with an exercise price of $4.50/share, (iv) 2,333 shares of common stock granted on May 1, 2020 with an exercise price of $4.50/share, (v) 1,167 shares of common stock granted on July 1, 2020 with an exercise price of $4.50/share, and (vi) 14,448 shares of common stock granted on January 1, 2021 with an exercise price of $4.50/share.

F2: The options in footnote (1) were to expire 10 years from their respective grant dates.

F3: Mr. Bentovim was granted options to purchase an aggregate of 72,153 shares of the issuer's common stock under the 2016 Plan on March 1, 2023, consisting of (i) options to purchase 24,051 shares of common stock, at an exercise price of $3.00 per share, which options vest on March 1, 2025, (ii) options to purchase 24,051 shares of common stock, at an exercise price of $2.50 per share, which options vest on March 1, 2026, and (ii) options to purchase 24,051 shares of common stock, at an exercise price of $2.00 per share, which options vest on March 1, 2027. The foregoing options are set to expire seven years from the grant date.